Objective Effectiveness and safety in patients with type 2 diabetes (metformin and sulfonylurea poor glycemic control) related data of sitagliptin and metformin and sulfonylurea therapy. Method 48 cases of type 2 diabetic patients were randomly divided into profit according to the proportion of 2:1 sitagliptin group and the placebo group, the two groups were treated for 24 weeks. Results Glenn dean with metformin or sulfonylureas hypoglycemic drugs combined use of 24 weeks can significantly reduce glycated hemoglobin (HbA1c) level (compared with the placebo group, HbA1c down 0.62%, compared with baseline (P<0.0001). Conclusion the Glenn dean with metformin or sulfonylureas hypoglycemic drugs combined use of safe and ef ective.
NETL
NSTL
万方数据
